

Ashwin Ananthakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6910490/publications.pdf>

Version: 2024-02-01

294
papers

25,611
citations

11651

70
h-index

8167

148
g-index

320
all docs

320
docs citations

320
times ranked

29720
citing authors

#	ARTICLE	IF	CITATIONS
1	Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 88-95.	4.4	23
2	Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 303-313.e6.	4.4	6
3	Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. Digestive Diseases and Sciences, 2022, 67, 622-628.	2.3	19
4	Yield and Predictors of Surveillance Colonoscopies in Older Adults With Long-standing Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, e1353-e1364.	4.4	2
5	Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e1323-e1337.	4.4	60
6	Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. Clinical Gastroenterology and Hepatology, 2022, 20, 1299-1305.e5.	4.4	21
7	Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts. Environmental Research, 2022, 207, 112222.	7.5	9
8	Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor \pm Antagonists in Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2022, 20, 2366-2372.e6.	4.4	14
9	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	8.1	18
10	Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype. Clinical Gastroenterology and Hepatology, 2022, 20, 2347-2357.e14.	4.4	4
11	Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. Inflammatory Bowel Diseases, 2022, 28, 1833-1837.	1.9	5
12	Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2022, 67, 5206-5212.	2.3	9
13	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	3.7	7
14	Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts. Alimentary Pharmacology and Therapeutics, 2022, 55, 225-233.	3.7	9
15	Sugars and Gastrointestinal Health. Clinical Gastroenterology and Hepatology, 2022, 20, 1912-1924.e7.	4.4	15
16	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.4	3
17	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology and Hepatology, 2022, 7, 666-678.	8.1	31
18	Issue Highlights. Clinical Gastroenterology and Hepatology, 2022, 20, 1195-1196.	4.4	0

#	ARTICLE	IF	CITATIONS
19	E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study. Digestive Diseases and Sciences, 2022, , .	2.3	1
20	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2021, 66, 3548-3554.	2.3	8
21	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 1800-1813.e4.	4.4	70
22	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clinical Gastroenterology and Hepatology, 2021, 19, 1366-1376.e2.	4.4	55
23	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2064-2071.e1.	4.4	8
24	Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records data. Biometrics, 2021, 77, 413-423.	1.4	4
25	Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 87-95.e4.	4.4	47
26	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 519-527.e5.	4.4	31
27	Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. Inflammatory Bowel Diseases, 2021, 27, 469-475.	1.9	8
28	Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study. Inflammatory Bowel Diseases, 2021, 27, 476-481.	1.9	3
29	A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 760-767.	2.3	12
30	Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. Clinical Gastroenterology and Hepatology, 2021, 19, 1226-1233.e1.	4.4	12
31	Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. Clinical Gastroenterology and Hepatology, 2021, 19, 939-946.e4.	4.4	25
32	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology, 2021, 160, 445-451.	1.3	33
33	Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 155-161.	1.9	48
34	Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. Inflammatory Bowel Diseases, 2021, 27, 779-786.	1.9	26
35	It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD. Clinical Gastroenterology and Hepatology, 2021, 19, 446-447.	4.4	1
36	Diet in Treatment of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 425-435.e3.	4.4	63

#	ARTICLE	IF	CITATIONS
37	Frailty in inflammatory bowel diseases: an emerging concept. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110254.	3.2	22
38	Economic burden and cost-effectiveness of therapies for <i>Clostridiodes difficile</i> infection: a narrative review. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110186.	3.2	30
39	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. Digestive Diseases and Sciences, 2021, 66, 4178-4190.	2.3	38
40	IBD risk prediction using multi-ethnic polygenic risk scores. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 217-218.	17.8	6
41	Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Digestive Diseases and Sciences, 2021, 66, 733-737.	2.3	1
42	Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 590-592.	1.9	0
43	Nutrition in the Management of Inflammatory Bowel Diseases. Gastroenterology Clinics of North America, 2021, 50, 151-167.	2.2	6
44	Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1541-1543.	1.9	21
45	Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. Clinical Gastroenterology and Hepatology, 2021, 19, 1108-1110.	4.4	6
46	High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, , 1.	2.3	3
47	Plant-Based Diet Quality and Risk of Crohnâ€™s Disease and Ulcerative Colitis in US Women. Current Developments in Nutrition, 2021, 5, 462.	0.3	1
48	Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host and Microbe, 2021, 29, 1294-1304.e4.	11.0	85
49	The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 754-769.	8.1	27
50	Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. Future Microbiology, 2021, 16, 1215-1227.	2.0	9
51	Immuneâ€™mediated diseases and risk of Crohnâ€™s disease or ulcerative colitis: a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 598-607.	3.7	16
52	Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study. Inflammatory Bowel Diseases, 2021, 27, 1740-1746.	1.9	12
53	Womenâ€™s Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 2021, , .	2.7	0
54	Frailty in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2021, 17, 263-268.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	4.4	22
56	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 14-23.	4.4	108
57	Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence. <i>Digestive Diseases and Sciences</i> , 2020, 65, 111-118.	2.3	20
58	Gastrointestinal Diseases. , 2020, , 16-26.		3
59	Association Between Vulvovaginal Discomfort and Activity of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 604-611.e1.	4.4	14
60	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 309-315.	1.3	31
61	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1133-1141.e3.	4.4	43
62	Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 347-355.	3.7	50
63	Use of Narrative Concepts in Electronic Health Records to Validate Associations Between Genetic Factors and Response to Treatment of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1890-1892.	4.4	2
64	Estimating average treatment effects with a double-index propensity score. <i>Biometrics</i> , 2020, 76, 767-777.	1.4	8
65	Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1926-1932.	1.9	23
66	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 872-880.e1.	4.4	16
67	Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions. <i>Crohn's & Colitis 360</i> , 2020, 2, otaa019.	1.1	1
68	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis 360</i> , 2020, 2, otaa039.	1.1	8
69	Multi-omic Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1524-1532.	1.9	36
70	Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1252-1260.	4.4	153
71	Reply. <i>Gastroenterology</i> , 2020, 159, 1993-1994.	1.3	0
72	Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 159, 873-883.e1.	1.3	96

#	ARTICLE	IF	CITATIONS
73	Sa1836 FRAILITY AS A RISK FACTOR FOR HOSPITAL READMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE STUDY. Gastroenterology, 2020, 158, S-445-S-446.	1.3	1
74	Clinical Research and Trialsâ€”A â€œNonessentialâ€”Victim of the COVID-19 Pandemic?. American Journal of Gastroenterology, 2020, 115, 946-947.	0.4	4
75	Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools. New England Journal of Medicine, 2020, 382, 1042-1052.	27.0	1
76	Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2020, 115, 340-349.	0.4	37
77	Frailty is independently associated with mortality in 11,001 patients with inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2020, 52, 311-318.	3.7	40
78	Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. Digestive Diseases and Sciences, 2020, 65, 3672-3678.	2.3	7
79	Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2020, 158, 2104-2111.e2.	1.3	81
80	Editorial: histologic normalisation in ulcerative colitis. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 401-401.	3.7	1
81	Management of Inflammatory Bowel Diseases: Clinical Perspectives. Clinical Gastroenterology and Hepatology, 2020, 18, 1249-1251.	4.4	1
82	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1381-1392.	4.4	161
83	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005â€”2016). Clinical Gastroenterology and Hepatology, 2020, 18, 2500-2509.e1.	4.4	27
84	The Doctor Will Call You Now! Telemedicine in the Midst of a Pandemic. Clinical Gastroenterology and Hepatology, 2020, 18, 1688-1690.	4.4	18
85	Impact of Diet on Risk of IBD. Crohn's & Colitis 360, 2020, 2, .	1.1	7
86	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1919.	4.4	0
87	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell, 2019, 178, 714-730.e22.	28.9	806
88	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 447-470.	1.4	34
89	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Advances in Therapy, 2019, 36, 3079-3095.	2.9	23
90	Tofacitinib: A Jak of All Trades. Clinical Gastroenterology and Hepatology, 2019, 17, 1438-1440.	4.4	6

#	ARTICLE	IF	CITATIONS
91	The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. <i>ELife</i> , 2019, 8, .	6.0	84
92	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Crohn's & Colitis</i> 360, 2019, 1, otz009.	1.1	13
93	Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. <i>Nature</i> , 2019, 569, 655-662.	27.8	1,638
94	Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 990-995.	1.3	6
95	Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1736-1743.e4.	4.4	76
96	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
97	CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2265-2272.	2.3	3
98	Comparative safety and effectiveness of tumor necrosis factor \pm antagonists and vedolizumab in elderly IBD patients: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 873-879.	3.7	76
99	High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). <i>Nature Protocols</i> , 2019, 14, 3426-3444.	12.0	94
100	ACG Clinical Guideline: Ulcerative Colitis in Adults. <i>American Journal of Gastroenterology</i> , 2019, 114, 384-413.	0.4	933
101	Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 502-509.e1.	4.4	69
102	Patient age determines adherence to preventive care measures among patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2019, 51, 178-179.	0.9	0
103	Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. <i>International Journal of Colorectal Disease</i> , 2019, 34, 491-499.	2.2	28
104	Cancer risk in microscopic colitis: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2019, 19, 1.	2.0	48
105	Fatigue in IBD: epidemiology, pathophysiology and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 247-259.	17.8	137
106	The Gut Microbiome and Digestive Health – A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 215-217.	4.4	7
107	Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 203-204.	4.4	9
108	Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 72-82.	0.1	15

#	ARTICLE	IF	CITATIONS
109	Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 559-567.	1.3	31
110	Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. <i>Digestive Diseases and Sciences</i> , 2018, 63, 738-745.	2.3	16
111	Enabling phenotypic big data with PheNorm. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 54-60.	4.4	82
112	Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. <i>Nature Microbiology</i> , 2018, 3, 337-346.	13.3	408
113	Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 525-531.	1.3	22
114	Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1840-1848.	1.9	34
115	Effect of oral tobacco use and smoking on outcomes of Crohn's disease in India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 134-140.	2.8	13
116	Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 190-197.e11.	4.4	84
117	Environmental triggers in IBD: a review of progress and evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 39-49.	17.8	573
118	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 99-105.	4.4	97
119	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , 2018, 32, 31-37.	1.9	7
120	Weekend Effect in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, 13-21.	0.4	31
121	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis Results From the Nurses' Health Study. <i>Gastroenterology</i> , 2018, 155, 1764-1775.e2.	1.3	24
122	Bugs and drugs: Predicting response to therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 27-27.	2.8	0
123	The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn's Disease in Children. <i>American Journal of Gastroenterology</i> , 2018, 113, 1524-1529.	0.4	33
124	Making sense of clinical predictors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 7-8.	2.8	0
125	Debate session: So what causes inflammatory bowel disease? It's all in the environment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 24-24.	2.8	5
126	The role of diet in the aetiopathogenesis of inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 525-535.	17.8	178

#	ARTICLE	IF	CITATIONS
127	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2634-2640.	1.9	20
128	Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2247-2257.	1.9	19
129	Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2445-2450.	2.3	12
130	The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2242-2246.	1.9	23
131	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1177.	4.4	0
132	Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2350-2359.	1.9	23
133	Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2740-2746.	2.3	10
134	Reply to "Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients". <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1256-1256.	1.3	23
135	Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1036-1041.	1.3	23
136	Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. <i>Scientific Reports</i> , 2018, 8, 12699.	3.3	37
137	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. <i>Nature Communications</i> , 2018, 9, 3347.	12.8	192
138	The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 814-823.	3.7	31
139	Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 269-276.	8.1	139
140	Genetic risk factors for serious infections in inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 570-576.	1.5	6
141	Modifiable Environmental Factors in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2017, 19, 21.	2.5	27
142	Management of Inflammatory Bowel Disease in the Elderly Patient. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 882-893.	1.9	75
143	Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1187-1194.	1.9	16
144	Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. <i>Cell Host and Microbe</i> , 2017, 21, 603-610.e3.	11.0	306

#	ARTICLE	IF	CITATIONS
145	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 162-168.	3.7	15
146	Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1088-1095.	1.9	29
147	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1291-1302.	3.7	230
148	Editorial: co-existing immune-mediated disease in inflammatory bowel diseases – a new disease severity indicator? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1168-1168.	3.7	0
149	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1590-1596.	2.3	56
150	A Comprehensive Study of Costs Associated With Recurrent <i>Clostridium difficile</i> Infection. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 196-202.	1.8	48
151	Filgotinib for Crohn's disease – expanding treatment options. <i>Lancet, The</i> , 2017, 389, 228-229.	13.7	4
152	Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary n3. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1898-1904.	1.9	30
153	Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1026-1027.	3.7	0
154	Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 780-789.	3.7	163
155	Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 645-656.	3.7	121
156	Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1121-1121.	3.7	0
157	Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2017, 62, 197-206.	2.3	45
158	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 3-13.	3.7	190
159	Surrogate-assisted feature extraction for high-throughput phenotyping. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e143-e149.	4.4	68
160	Asians Have More Perianal Crohn Disease and Ocular Manifestations Compared with White Americans. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 147-153.	1.9	21
161	Pivot to Asia: inflammatory bowel disease burden. <i>Intestinal Research</i> , 2017, 15, 138.	2.6	80
162	The emergence of <i>Clostridium difficile</i> infection in Asia: A systematic review and meta-analysis of incidence and impact. <i>PLoS ONE</i> , 2017, 12, e0176797.	2.5	77

#	ARTICLE	IF	CITATIONS
163	Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2016, 7, 554.	4.8	42
164	<scp>HBV</scp>/<scp>HIV</scp> coinfection is associated with poorer outcomes in hospitalized patients with <scp>HBV</scp> or <scp>HIV</scp>. <i>Journal of Viral Hepatitis</i> , 2016, 23, 820-829.	2.0	36
165	<i>Clostridium difficile</i> associated risk of death score (<scp>CARDS</scp>): a novel severity score to predict mortality among hospitalised patients with <i>C. difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 725-733.	3.7	65
166	Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 151-158.	1.9	16
167	Environmental Hygiene and Risk of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2191-2199.	1.9	63
168	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 151, 97-109.e4.	1.3	120
169	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2627-2635.	2.3	15
170	P-014 Circulating C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S13-S14.	1.9	0
171	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1173-1182.	3.0	15
172	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. <i>Gastroenterology</i> , 2016, 151, 724-732.	1.3	109
173	Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 52-60.	3.7	22
174	Infliximab or ciclosporin for acute severe ulcerative colitis?. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 2-3.	8.1	2
175	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016, 7, 12342.	12.8	50
176	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 880-885.	1.9	44
177	Toward reducing bias in clinical trials: central readers for endoscopic endpoints. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 198-200.	1.0	4
178	Metagenomic Characterization of Microbial Communities In Situ Within the Deeper Layers of the Ileum in Crohn's Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 563-566.e5.	4.5	23
179	Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 561-568.	2.0	9
180	Chromoendoscopy Is Better: So Why Am I Not (yet) Using it for Routine Inflammatory Bowel Disease Surveillance?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 720-722.	4.4	10

#	ARTICLE	IF	CITATIONS
181	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 818-824.e6.	4.4	61
182	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 973-979.	4.4	56
183	Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1224-1236.	1.3	122
184	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , 2016, 86, 62-70.	3.3	30
185	Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. <i>American Journal of Medicine</i> , 2016, 129, 628-634.	1.5	10
186	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 58-64.	4.4	93
187	Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 120-120.	3.7	0
188	High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	80
189	New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 972-979.	3.7	52
190	Development of phenotype algorithms using electronic medical records and incorporating natural language processing. <i>BMJ, The</i> , 2015, 350, h1885-h1885.	6.0	226
191	Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	45
192	Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2507-2514.	1.9	30
193	Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. <i>International Journal of Epidemiology</i> , 2015, 44, 1995-2005.	1.9	83
194	The Toronto Consensus Guidelines for Nonhospitalized Ulcerative Colitis: A Welcome Update but Not the End of the Story. <i>Gastroenterology</i> , 2015, 148, 877-880.	1.3	1
195	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1703-1704.	4.4	0
196	Colonoscopy Is Associated With a Reduced Risk for Colon Cancer and Mortality in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 322-329.e1.	4.4	107
197	Surgery for Crohn's disease: look harder, act faster. <i>Lancet, The</i> , 2015, 385, 1370-1371.	13.7	9
198	Epidemiology and risk factors for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 205-217.	17.8	1,202

#	ARTICLE	IF	CITATIONS
199	High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2136-2143.	2.3	45
200	Mode of Childbirth and Long-Term Outcomes in Women with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2015, 60, 471-477.	2.3	27
201	Patient Electronic Health Records as a Means to Approach Genetic Research in Gastroenterology. <i>Gastroenterology</i> , 2015, 149, 1134-1137.	1.3	3
202	Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1197-1200.	4.4	47
203	Measures of Obesity and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 361-368.	1.9	123
204	Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1141-1148.	3.7	38
205	The Holy Grail, or Only Half Way There?. <i>Gastroenterology</i> , 2015, 148, 8-10.	1.3	2
206	Environmental Risk Factors for Inflammatory Bowel Diseases: A Review. <i>Digestive Diseases and Sciences</i> , 2015, 60, 290-298.	2.3	136
207	Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts. <i>PLoS ONE</i> , 2015, 10, e0136651.	2.5	82
208	Early life environment and natural history of inflammatory bowel diseases. <i>BMC Gastroenterology</i> , 2014, 14, 216.	2.0	34
209	Pretreatment 25-Hydroxyvitamin D Levels and Durability of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 385-391.	2.6	98
210	Evaluation of matched control algorithms in EHR-based phenotyping studies: A case study of inflammatory bowel disease comorbidities. <i>Journal of Biomedical Informatics</i> , 2014, 52, 105-111.	4.3	21
211	Higher plasma vitamin D is associated with reduced risk of <i>Clostridium difficile</i> infection in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1136-1142.	3.7	56
212	Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case-control study. <i>BMC Infectious Diseases</i> , 2014, 14, 661.	2.9	15
213	Genetic Polymorphisms in Metabolizing Enzymes Modifying the Association Between Smoking and Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 783-789.	1.9	34
214	Thromboprophylaxis Is Associated With Reduced Post-hospitalization Venous Thromboembolic Events in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1905-1910.	4.4	61
215	Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 956-963.	1.3	49
216	Cost-effectiveness of Competing Strategies for Management of Recurrent <i>Clostridium difficile</i> Infection: A Decision Analysis. <i>Clinical Infectious Diseases</i> , 2014, 58, 1507-1514.	5.8	128

#	ARTICLE	IF	CITATIONS
217	Association Between Reduced Plasma 25-Hydroxy Vitamin D and Increased Risk of Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 821-827.	4.4	101
218	Differential Effect of Genetic Burden on Disease Phenotypes in Crohn's Disease and Ulcerative Colitis: Analysis of a North American Cohort. <i>American Journal of Gastroenterology</i> , 2014, 109, 395-400.	0.4	77
219	Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. <i>Gut</i> , 2014, 63, 776-784.	12.1	386
220	Review article: vitamin D and inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 125-136.	3.7	181
221	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1879-1886.	4.4	76
222	Serum Inflammatory Markers and Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1342-1348.e1.	4.4	38
223	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1577-1578.	4.4	0
224	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 845-851.	1.3	46
225	Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 37-44.	1.9	43
226	Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 309-315.	1.9	127
227	Treatment of Intra-Abdominal Abscesses in Crohn's Disease: A Nationwide Analysis of Patterns and Outcomes of Care. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2013-2018.	2.3	23
228	Interobserver Agreement for the Detection of Barrett's Esophagus with Optical Frequency Domain Imaging. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2261-2265.	2.3	43
229	Dyssynergic Defecation: A Treatable Cause of Persistent Symptoms When Inflammatory Bowel Disease Is in Remission. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3600-3605.	2.3	32
230	A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 970-977.	1.3	494
231	Personalizing therapy for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 549-558.	3.0	10
232	Sleep Disturbance and Risk of Active Disease in Patients With Crohn's Disease and Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 965-971.	4.4	192
233	Association Between Depressive Symptoms and Incidence of Crohn's Disease and Ulcerative Colitis: Results From the Nurses' Health Study. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 57-62.	4.4	123
234	Antibiotic exposure is associated with development of inflammatory bowel disease. <i>Journal of Pediatrics</i> , 2013, 162, 1077.	1.8	1

#	ARTICLE	IF	CITATIONS
235	Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 445-454.	3.7	101
236	Impact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2013, 108, 1123-1129.	0.4	48
237	Guidelines for Diagnosis, Treatment, and Prevention of <i>Clostridium difficile</i> Infections. <i>American Journal of Gastroenterology</i> , 2013, 108, 478-498.	0.4	1,413
238	Similar Risk of Depression and Anxiety Following Surgery or Hospitalization for Crohn's Disease and Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2013, 108, 594-601.	0.4	72
239	Environmental Triggers for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2013, 15, 302.	2.5	91
240	Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 107-112.	1.3	155
241	Improving Case Definition of Crohn's Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1411-1420.	1.9	142
242	Genetic risk factors for <i>Clostridium difficile</i> infection in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 522-530.	3.7	49
243	Weekend hospitalisations and post-operative complications following urgent surgery for ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 895-904.	3.7	35
244	Normalization of Plasma 25-Hydroxy Vitamin D Is Associated with Reduced Risk of Surgery in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	168
245	Early Life Factors and Risk of Inflammatory Bowel Disease in Adulthood. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 542-547.	1.9	50
246	P-056: Aryl Hydrocarbon Receptor Expression: A Comparison Between Patients with IBD and Healthy Controls, and Association with Serum Fatty Acids. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S49-S50.	1.9	0
247	How Does Genotype Influence Disease Phenotype in Inflammatory Bowel Disease?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	14
248	Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 2012, 156, 350.	3.9	223
249	Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2012, 13, 472-477.	1.5	8
250	Geographical variation and incidence of inflammatory bowel disease among US women. <i>Gut</i> , 2012, 61, 1686-1692.	12.1	187
251	Detecting and Treating <i>Clostridium Difficile</i> Infections in Patients with Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 339-353.	2.2	30
252	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	27.8	4,038

#	ARTICLE	IF	CITATIONS
253	Reply to Dr. McNabb-Baltar's letter. Journal of Crohn's and Colitis, 2012, 6, 868.	1.3	0
254	Predictors of severe outcomes associated with <i>Clostridium difficile</i> infection in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2012, 35, 789-795.	3.7	79
255	Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 459-466.	3.7	48
256	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Digestive Diseases and Sciences, 2012, 57, 472-480.	2.3	18
257	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. American Journal of Gastroenterology, 2011, 106, 2009-2017.	0.4	44
258	Clostridium difficile infection: epidemiology, risk factors and management. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 17-26.	17.8	313
259	Geographic variation and the incidence of inflammatory bowel disease among U.S. women. Inflammatory Bowel Diseases, 2011, 17, S15.	1.9	0
260	Fracture-Associated Hospitalizations in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2011, 56, 176-182.	2.3	20
261	Deep Vein Thrombosis and Pulmonary Embolism in Hospitalized Patients with Cirrhosis: A Nationwide Analysis. Digestive Diseases and Sciences, 2011, 56, 2152-2159.	2.3	71
262	A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations. Journal of Gastrointestinal Surgery, 2011, 15, 267-276.	1.7	62
263	Physician density and hospitalization for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 633-638.	1.9	7
264	Ambient air pollution correlates with hospitalizations for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1138-1145.	1.9	127
265	Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 976-983.	1.9	130
266	Impact of Autonomic Dysfunction on Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2010, 44, 272-279.	2.2	25
267	Laparoscopic Resection for Inflammatory Bowel Disease: Outcomes from a Nationwide Sample. Journal of Gastrointestinal Surgery, 2010, 14, 58-65.	1.7	21
268	Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer. Journal of General Internal Medicine, 2010, 25, 1164-1171.	2.6	60
269	Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. Inflammatory Bowel Diseases, 2010, 16, 494-500.	1.9	24
270	Clostridium difficile and inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1445-1446.	1.9	4

#	ARTICLE	IF	CITATIONS
271	Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflammatory Bowel Diseases, 2010, 16, 1532-1540.	1.9	37
272	Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV. Journal of Viral Hepatitis, 2010, 17, 720-729.	2.0	19
273	Trends in Ambulatory and Emergency Room Visits for Inflammatory Bowel Diseases in the United States: 1994-2005. American Journal of Gastroenterology, 2010, 105, 363-370.	0.4	48
274	A Novel Risk Score to Stratify Severity of Crohn's Disease Hospitalizations. American Journal of Gastroenterology, 2010, 105, 1799-1807.	0.4	55
275	Length of Office Visits for Gastrointestinal Disease: Impact of Physician Specialty. American Journal of Gastroenterology, 2010, 105, 1719-1725.	0.4	6
276	Improved Efficacy of Biological Maintenance Therapy in "Early" Compared With "Late" Crohn's Disease: Strike While the Iron Is Hot With Anti-TNF Agents?. American Journal of Gastroenterology, 2010, 105, 1583-1585.	0.4	9
277	Clostridium Difficile and Inflammatory Bowel Disease. Medical Clinics of North America, 2010, 94, 135-153.	2.5	40
278	Impact of Clostridium difficile on inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2010, 4, 589-600.	3.0	31
279	Treatment of Ulcerative Colitis in the Elderly. Digestive Diseases, 2009, 27, 327-334.	1.9	34
280	Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations. Inflammatory Bowel Diseases, 2009, 15, 182-189.	1.9	175
281	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 176-181.	1.9	67
282	Higher hospital volume predicts endoscopy but not the in-hospital mortality rate in patients with acute variceal hemorrhage. Gastrointestinal Endoscopy, 2009, 69, 221-229.	1.0	9
283	Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. Gastrointestinal Endoscopy, 2009, 70, 422-432.	1.0	24
284	Outcomes of Weekend Admissions for Upper Gastrointestinal Hemorrhage: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 296-302.e1.	4.4	153
285	Clostridium Difficile and Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2009, 38, 711-728.	2.2	59
286	Effect of hospital volume and teaching status on outcomes of acute liver failure. Liver Transplantation, 2008, 14, 1347-1356.	2.4	28
287	Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut, 2008, 57, 205-210.	12.1	364
288	Does It Matter Where You Are Hospitalized for Inflammatory Bowel Disease? A Nationwide Analysis of Hospital Volume. American Journal of Gastroenterology, 2008, 103, 2789-2798.	0.4	115

#	ARTICLE	IF	CITATIONS
289	Permanent Work Disability in Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 154-161.	0.4	90
290	Racial Differences in Liver Transplantation Outcomes in the MELD Era. American Journal of Gastroenterology, 2008, 103, 901-910.	0.4	72
291	Severe Pulmonary Toxicity After Azathioprine/6-Mercaptopurine Initiation for the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2007, 41, 682-688.	2.2	55
292	Disparities in Colon Cancer Screening in the Medicare Population. Archives of Internal Medicine, 2007, 167, 258.	3.8	117
293	Caroli's disease: Identification and treatment strategy. Current Gastroenterology Reports, 2007, 9, 151-155.	2.5	48
294	Epidemiology of Primary and Secondary Liver Cancers. Seminars in Interventional Radiology, 2006, 23, 047-063.	0.8	150